EXICURE, INC.
Close on Oct 19, 2026
- Market cap
- $6.57M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 7, 2025 | During market hours | – | $-0.39 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 8, 2025 | During market hours | – | $-0.41 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 18, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | During market hours | – | $-0.57 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 16, 2024 | During market hours | – | $-0.61 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Jul 14, 2023 | During market hours | – | $-0.70 | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 27, 2023 | During market hours | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 14, 2022 | During market hours | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 15, 2022 | During market hours | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 16, 2022 | During market hours | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 25, 2022 | During market hours | – | – | – |
Press releases
Announcements Exicure filed with the SEC
EXICURE ANNOUNCES RECEIPT OF NASDAQ DELINQUENCY NOTICE AND FILING OF FORM 10-Q
Regulation FD disclosure · EX-99.1 to Form 8-K
IN RE EXICURE, INC. DERIVATIVE LITIGATION
Other events · EX-99.1 to Form 8-K
UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION
Other events · EX-99.2 to Form 8-K
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Other events · EX-99.3 to Form 8-K
Exicure, Inc. Reports Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Exicure, Inc. Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Exicure, Inc. Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Exicure, Inc. ( Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
Other events · EX-99.1 to Form 8-K
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
Listing notice · Other events · EX-99 to Form 8-K
Exicure, Inc. Reports Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
UNAUDITED PROFORMA CONSOLIDATED BALANCE SHEETS
Other events · EX-99.1 to Form 8-K
Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results
Material agreement · Results of operations · Unregistered share sale · EX-99.1 to Form 8-K
Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
Regulation FD disclosure · EX-99.1 to Form 8-K
Exicure, Inc. Announces 1-for-5 Reverse Stock Split
Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting
Other events · EX-99.1 to Form 8-K
Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
Other events · EX-99.1 to Form 8-K
Exicure, Inc. Receives Positive Listing Determination from Nasdaq
Regulation FD disclosure · EX-99.1 to Form 8-K
Exicure, Inc. Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Exicure, Inc. Reports Full Year 2023 Financial Results
Results of operations · New financial obligation · EX-99.1 to Form 8-K
Exicure, Inc. Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
Regulation FD disclosure · EX-99.1 to Form 8-K
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives
Regulation FD disclosure · EX-99.1 to Form 8-K
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld
Regulation FD disclosure · EX-99.1 to Form 8-K
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors
Regulation FD disclosure · EX-99 to Form 8-K
Exicure, Inc. Reports Full Year 2022 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements
Agreement terminated · Other events · EX-99.1 to Form 8-K
Exicure, Inc. Reports Third Quarter 2022 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Exicure, Inc. Enters into Definitive Agreement with CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives
Material agreement · Exit or restructuring costs · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress
Results of operations · EX-99.1 to Form 8-K
Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement
Other events · EX-99.1 to Form 8-K
Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split
Listing notice · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders
Other events · EX-99.1 to Form 8-K
Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress
Results of operations · EX-99.1 to Form 8-K
Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress
Results of operations · EX-99.1 to Form 8-K